Hims & Hers Health, Inc. (HIMS) Hims & Hers Health, Inc. operates a comprehensive digital health platform that seamlessly links individuals with licensed medical professionals for virtual consultations and ongoing care. Through its user-friendly websites and mobile app, the company delivers a diverse portfolio of health and wellness solutions directly to consumers. This includes access to recurring prescription medications, alongside a wide selection of over-the-counter drugs, devices, cosmetics, and dietary supplements. Its core focus areas are general wellness, sexual health, skincare, and hair care. Specific non-prescription offerings span categories such as: Wellness: encompassing items like vitamin C, melatonin, biotin, and collagen protein supplements. Skincare: including products such as moisturizers, serums, and face washes. Sexual Health: providing essentials like condoms, climax delay sprays and wipes, vibrators, and lubricants. Hair Care: offering specialized shampoos, conditioners, scalp scrubs, and topical treatments like minoxidil. Beyond direct sales, Hims & Hers also distributes health and wellness products via wholesale partnerships. The company's headquarters are located in San Francisco, California.
Sector: Services-Offices & Clinics of Doctors of Medicine
Industry: Medical - Care Facilities
Hims & Hers Health, Inc. NYSE:HIMS Healthcare · Medical - Care Facilities
AH Close $27.79 vs close AH Close $27.79 +0.29% vs close
All Press Release SEC Filings News
News
Hims & Hers Health, Inc. (HIMS) Declines More Than Market: Some Information for Investors
zacks.com • 2d ago News
Hims & Hers Defends Subscription Practices And Privacy Disclosures Against Lawsuit
benzinga.com • 2d ago Press Release ⚠ 4
Hims & Hers Health (HIMS) Facing Securities Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower
Hagens Berman announced a securities class action against Hims & Hers and certain executives, with a class period of Aug. 4, 2025 to July 29, 2026 and a lead plaintiff deadline of Nov. 2, 2026.
The suit follows the FTC's July 29, 2026 federal complaint — joined by Utah and Los Angeles County — alleging deceptive sharing of sensitive health data with Meta and Snap and ROSCA-violating subscription billing practices.
The stock fell $4.32 (-14.7%) on the complaint's reveal, erasing over $970 million of market cap in a day.
This release itself is a plaintiff-firm solicitation seeking investors and whistleblowers; it introduces no new issuer disclosure beyond the litigation follow-on.
• 3d ago AI analysis › Press Release ⚠ 2
Hims Expands Testosterone Care with Injectable and Oral TRT, Its Largest Men’s Health Launch to Date
Hims & Hers launched injectable and oral testosterone replacement therapy options, its largest men's health expansion since introducing the category last September.
The new lineup includes two injectables (a twice-weekly compounded option and once-weekly generic testosterone cypionate) plus Kyzatrex, an FDA-approved oral TRT shown to help up to 96% of men reach normal testosterone levels within 90 days.
The expansion targets an estimated 20 million U.S. men with low testosterone and builds on Testosterone Rx+, which the company says was scaling faster than any specialty outside weight loss as of Q2 2026.
• 4d ago AI analysis › Press Release ⚠ 3
Hims & Hers Health (NYSE: HIMS) Facing Securities Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower
Hagens Berman issued a solicitation notice announcing a securities class action against Hims & Hers Health and certain executives, with a class period of Aug. 4, 2025 through July 29, 2026 and a lead plaintiff deadline of Nov. 2, 2026.
The lawsuit follows the FTC's July 29, 2026 federal complaint (joined by Utah and Los Angeles County) alleging deceptive sharing of consumer health data with Meta and Snap, and ROSCA violations tied to subscription billing and cancellation barriers.
The release notes HIMS shares fell $4.32 (-14.7%) on the complaint's reveal, erasing over $970 million in market cap — but the release itself is law-firm marketing, not new company disclosure.
• 5d ago AI analysis › Press Release
Hims & Hers to Announce Third Quarter 2026 Financial Results on November 9, 2026
Hims & Hers Health (NYSE: HIMS) will report third quarter 2026 financial results after market close on Monday, November 9, 2026.
A live conference call to discuss the results is scheduled for 5:00 p.m. ET the same day, with dial-in numbers for U.S. and international participants and a webcast at investors.hims.com.
This is a scheduling notice only; no results or guidance were disclosed.
• 13d ago AI analysis › Press Release
Hers Launches in Australia, Built to Care for the Whole Woman
Hims & Hers officially launched Hers in Australia, rebranding its Eucalyptus-owned Juniper women's health platform and introducing treatment programs across hair regrowth, menopause and perimenopause, and weight management.
The launch follows Pilot's transition to Hims in August and completes the company's full platform rollout in Australia, building on its acquisition of Eucalyptus earlier this year.
The expansion taps a telehealth market projected to grow from roughly $542 million to $2.56 billion by 2034, extending Hers' model into one of the fastest-growing digital health markets.
• 13d ago AI analysis › Recent SEC filings with analysis 
